SetPoint Medical is a technology company.
SetPoint Medical has raised $364.0M across 8 funding rounds.
SetPoint Medical has raised $364.0M in total across 8 funding rounds.
SetPoint Medical is a commercial-stage medical technology company developing implantable neurostimulation devices to treat chronic autoimmune diseases by modulating the vagus nerve.[1][2][3] Its flagship SetPoint System is an FDA-approved (July 2025), first-of-its-kind neuroimmune modulation therapy for adults with moderate-to-severe rheumatoid arthritis (RA) who inadequately respond to or cannot tolerate biologic or targeted synthetic drugs.[2][4][5] The device—a small, rechargeable implant placed on the left vagus nerve—delivers precise one-minute daily electrical pulses to activate anti-inflammatory pathways, reducing proinflammatory cytokines by 30-70% and restoring immunologic balance, with therapy lasting up to 10 years on a single charge cycle.[2][4][5][6] It serves RA patients (over 1.5 million in the U.S.) and rheumatology providers, offering a non-drug alternative with potentially lower risk, cost, and immunosuppression than ongoing therapies.[1][2][4] Growth momentum includes FDA Breakthrough Device Designation, CMS Transitional Pass-Through Payment approval, and U.S. launch plans in targeted cities by late 2025, expanding nationwide in early 2026, alongside evaluations for multiple sclerosis and Crohn's disease.[2][4]
Founded in 2007, SetPoint Medical emerged from over 20 years of research identifying specific vagus nerve fibers and stimulation parameters to trigger anti-inflammatory responses without broad immunosuppression.[3][5][6] The company's mission integrates scientific discovery, precision engineering, and commercialization to address unmet needs in autoimmune diseases like RA, multiple sclerosis, and inflammatory bowel disease.[1][3] Key leadership includes CEO Murthy V. Simhambhatla, Ph.D., who leads commercialization efforts post-FDA approval, alongside executives like David Chernoff, MD, and a board featuring investors from New Enterprise Associates, Norwest Venture Partners, and others.[2][3] Pivotal moments include the landmark RESET-RA clinical trial proving safety and efficacy, FDA approval in July 2025 via the Breakthrough Devices Program, and CMS reimbursement approval, enabling commercial rollout.[2][4][5]
SetPoint rides the neuromodulation wave in medtech, shifting autoimmune treatment from lifelong drugs to precise, restorative devices amid rising biologic failures (many RA patients inadequately managed).[1][2][6] Timing aligns with maturing vagus nerve research, FDA's Breakthrough pathway for innovative devices, and payer pressures for cost-effective alternatives to expensive DMARDs.[2][4] Market forces favoring it include the $50B+ RA therapeutics market, growing demand for non-pharmacologic options amid drug side effects and resistance, and expansion potential to MS and Crohn's.[1][2] SetPoint influences the ecosystem by pioneering neuroimmune modulation, potentially redefining care standards, enabling provider adoption via familiar implantation techniques, and spurring competitor innovation in bioelectronic medicine.[3][5][6]
SetPoint is poised for rapid U.S. scaling post-2025 launch, with CMS coverage ensuring reimbursement and early 2026 nationwide expansion.[2][4] Upcoming trials for MS and Crohn's could broaden its platform, tapping adjacent autoimmune markets while leveraging RA momentum.[2] Trends like AI-optimized stimulation, outpatient procedures, and payer prioritization of durable devices will amplify growth, evolving SetPoint from RA pioneer to multi-indication leader in neuroimmune therapies—transforming chronic disease management as its vagus nerve platform proves drug alternatives at scale.[2][3][6]
SetPoint Medical has raised $364.0M in total across 8 funding rounds.
SetPoint Medical's investors include Action Potential Venture Capital, Morgenthaler Ventures, New Enterprise Associates (NEA), Norwest Venture Partners, Runway Growth Capital, Shangbay Capital.
SetPoint Medical has raised $364.0M across 8 funding rounds. Most recently, it raised $120.0M Series D in August 2025.